| Literature DB >> 28035988 |
Anthony Ayodeji Adegoke1,2,3, Adekunle Christopher Faleye4, Gulshan Singh5, Thor Axel Stenström6.
Abstract
The increasing threat to global health posed by antibiotic resistance remains of serious concern. Human health remains at higher risk due to several reported therapeutic failures to many life threatening drug resistant microbial infections. The resultant effects have been prolonged hospital stay, higher cost of alternative therapy, increased mortality, etc. This opinionated review considers the two main concerns in integrated human health risk assessment (i.e., residual antibiotics and antibiotic resistant genes) in various compartments of human environment, as well as clinical dynamics associated with the development and transfer of antibiotic resistance (AR). Contributions of quorum sensing, biofilms, enzyme production, and small colony variants in bacteria, among other factors in soil, water, animal farm and clinical settings were also considered. Every potential factor in environmental and clinical settings that brings about AR needs to be identified for the summative effects in overall resistance. There is a need to embrace coordinated multi-locational approaches and interrelationships to track the emergence of resistance in different niches in soil and water versus the hospital environment. The further integration with advocacy, legislation, enforcement, technological innovations and further research input and recourse to WHO guidelines on antibiotic policy would be advantageous towards addressing the emergence of antibiotic resistant superbugs.Entities:
Keywords: antimicrobial resistance; critical control point; exposure; health risk assessment; residual antibiotics; superbug; total antibiotic resistance
Mesh:
Substances:
Year: 2016 PMID: 28035988 PMCID: PMC6155606 DOI: 10.3390/molecules22010029
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Reported sub-lethal concentrations of residual antibiotics (RAbs) and antibiotic resistance genes (ARGs) in soil, aquatic environments and other related strata of the environment.
| Environment | Source | RAb/ARGs | Reported Concentration | Country | References |
|---|---|---|---|---|---|
| Soil | Soil | CIP | 2.77 μg/kg | Pakistan | [ |
| OFL | 2.98 μg/kg | ||||
| LEV | 3.35 μg/kg | ||||
| OXT | 4.53 μg/kg | ||||
| DOX | 3.12 μg/kg | ||||
| Grape soil | (39.19 ± 0.77) × 10−2 | China | [ | ||
| (0.42 ± 0.08) × 10−3 | |||||
| (0.48 ± 0.10) × 10−3 | |||||
| (0.02 ± 0.00) × 10−3 | |||||
| (0.44 ± 0.07) × 10−3 | |||||
| (10.55 ± 1.23) × 10−2 | |||||
| Soil | SMT | 0.01 μg/g | China | [ | |
| OTC | 0.02 μg/g | ||||
| Vegetable soil | TET | 8400 μg/kg | China | [ | |
| Animal manure | BAC | 0.01–1.76 mg/kg | Canada | [ | |
| Aquatic Environment | Wastewater | CIP | 3.0–5.25 mg/L | Pakistan | [ |
| LEV | 0–6.20 mg/L | ||||
| OFL | 2.45–4.12 mg/L | ||||
| OTC | 0–9.40 mg/L | ||||
| DOX | 1.58–6.75 mg/L | ||||
| AMX | 6.94 μg/L | Australia | [ | ||
| CIP | 0.72 μg/L | Hong Kong | [ | ||
| OFL | 0.60 μg/L | Italy | [ | ||
| ERY | 2.5–6.0 μg/L | Germany | [ | ||
| Surface water | OFL | 0.31 μg/L | Italy | [ | |
| Hospital effluents | AMX | 35.12 μg/L | Brazil | [ | |
| AMP | 389.13 μg/L | ||||
| CFX | 300.1 μg/L | ||||
| PEN G | 434.46 μg/L |
Key: AMX = Amoxicillin; BAC = Bacitracin; CFX = Cefotaxime; CIP = Ciprofloxacin; DOX = Doxytetracycline; ERY = Erythromycin; LEV = Levofloxacin; OTC = Oxytetracycline; OFL = Ofloxacin; PEN G = Penicillin G; SMT = Sulphamethaxazole; TET = Tetracycline.
Figure 1Percentage self-medication in some developed and mid-economic developed countries (Adapted from: http://www.abimip.org.br/uploads/material_de_ apoio/1296056417_792.pdf/).
Some reported AMR classified as having serious threat.
| Bacteria Threat Level | Examples of Reported Antibiotics/Antibiotic Groups to Which Resistance Occurred | Countries Where This Has Been Reported | References |
|---|---|---|---|
| Pan drug resistant (PDR)/Extended spectrum drug resistant (XDR) | Resistant to at least 3 classes + Carbapenems, polymyxins, tigecycline or fluoroquinolones | Greece, US, India, South Africa, Iran, Greece | [ |
| Drug resistant | Range of 45% to 94.7% resistant to Erythromycin, azithromycin, clindamycin, telithromycin, ciprofloxacin, | US; Finland; Poland; Philippines; China; Nigeria | [ |
| Fluconazole-resistant | 8.0%–98.8% resistant to Itraconazole, voriconazole, caspofungin, echinocandin, amphotericin B deoxycholate, fluconazole | US, UK, Argentina, Spain, China, South Africa | [ |
| Extended spectrum β-lactamase producing Enterobacteriaceae (ESBLs) | 23% to 85.1% resistant to cephalosporins, gentamicin, kanamycin, streptomycin, nalidixic acid, ciprofloxacin, tetracycline, chloramphen-icol, sulfamethoxazole | US, Switzerland, Netherland, Saudi Arabia, France, Germany, Czech Republic, Sweden | [ |
| Vancomycin-resistant | ≤90% ampicillin, chloramphen-icol, clindamycin, ciproflo-xin, erythromycin, neomycin, penicillin, rifampicin, tetracycline and vancomycin | US, Spain, Portugal Sweden, UK, Australia, Iran, Ethiopia | [ |
| Multidrug-resistant | 20% to 85.7% Cefepime, piperacillin-tazobactam, piperacillin, amikacin, levofloxacin, ciprofloxacin, Ofloxacin, meropenem, etc. | US, India, Germany South African, Nigeria, Greece | [ |
| Drug-resistant Non-typhoidal | ≤100% resistant to nalidixic acid, tetracycline, streptomycin, ciprofloxacin, azithromycin and cefotaxime | US, Iran, Egypt, Ethiopia, UK, China, Congo Republic, Saudi Arabia, Greece | [ |
| Drug-resistant | Resistant to ceftriaxone, cefuroxime, amoxicillin, ampicillin, ciprofloxacin and augmentin | US, Nigeria, India, Southern Asia and Kenya | [ |
| Methicillin-resistant | Usually resistant to wide range of beta lactam antibiotics to ≤100% | US, Nigeria, South Africa, Tanzania, several countries in Europe | [ |
| Drug-resistant | e.g., 37% were resistant to erythromycin, 29.6% to cefotaxime, 7.4% to levofloxacin, and 14.8% were identified as multidrug resistant | US, Spain, India, Austria Belgium, France, Germany, Italy, Portugal, Spain and Switzerland | [ |
| Total Drug-resistant | >30 cases of TDR-TB reported. 32% of patients with MDR-TB exhibited resistance to a fluoroquinolone | India, Iran, Italy and South Africa | [ |
Bacterial attributes besides selection for ARGs that facilitates AMR.
| Attributes/Mechanism | Application/Example (s) | Reference (s) |
|---|---|---|
| Quorum sensing | Mediated by accessory gene regulator (agr) | [ |
| Biofilm formation | Increased interaction of high population densities and close distant cells in biofilms for genetic exchange among mixed microbial communities converting biofilms to hotspots for antibiotic resistance | [ |
| Enzyme production | Beta lactamases, extended spectrum beta lactamase, metallo beta lactamase, etc. induced by exposure to imipenem and piperacillin in | [ |
| Mutation | The evolution of AMR under the sub-MIC arises progressively as low-cost mutations (e.g., duplications and amplifications) in high frequency (Canton and Morosini, 2011) | [ |
| Small colony variant (SMV) | Down-regulation of the bacterial electron transport and/or dihydrofolate reductase (DHFR) pathway sulfamethoxazole resistance, bringing about small colonial form GacS-GacA system | [ |
| Target change | C1 metabolism e.g., Trimethoprim, Sulfamethoxazole, Daptomycin, Colistin, Gentamicin, streptomycin, spectinomycin etc. | [ |
Figure 2The interrelatedness of contributing factors to AMR (AMR Microbes, RAbs and ARGs are recycled in nature).